Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:canBe |
anticancer agent
|
| gptkbp:CASNumber |
1018899-04-1
|
| gptkbp:developedBy |
Critical Outcome Technologies Inc.
|
| gptkbp:hasMolecularFormula |
C24H25FN4O
|
| gptkbp:hasSMILES |
COC1=CC(=C(C(=C1OC)OC)C=C(C#N)C(=O)NCCNC2=CC=CC=N2)C
|
| gptkbp:hasUNII |
2Q1K1N2V6E
|
| https://www.w3.org/2000/01/rdf-schema#label |
COTI2
|
| gptkbp:isApprovedDrug |
true
|
| gptkbp:IUPACName |
(E)-2-cyano-3-(2,4,6-trimethoxyphenyl)-N-(2-(pyridin-2-ylamino)ethyl)acrylamide
|
| gptkbp:mechanismOfAction |
p53 pathway modulator
|
| gptkbp:PubChem_CID |
CHEMBL2103887
25185716 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
COTI-2
|
| gptkbp:target |
TP53 protein
|
| gptkbp:bfsParent |
gptkb:Coreopsis_tinctoria
|
| gptkbp:bfsLayer |
7
|